Radiation Therapy and Erectile Function: Why the Decline Comes Later

Men who choose radiation for prostate cancer are usually told that erectile function is better preserved than with surgery. That is true in the first years after treatment. It leads many men to conclude, six months out, that they were among the fortunate ones. The pattern of radiation-induced erectile dysfunction is different from the surgical pattern, and it does not declare itself early.

This article explains the timeline, the mechanism behind it, what the long-term trial data actually show, and what can be done at each stage.

Two different patterns of loss

After radical prostatectomy, erectile dysfunction begins immediately. The nerves running alongside the prostate are stretched, dissected, or removed, and function is lost at once. What follows is a recovery curve: partial return over twelve to twenty-four months in men whose nerves were spared, less in men whose nerves were not.

Radiation produces the opposite shape. Function is usually intact in the weeks after treatment ends, then declines gradually over the following two to three years. The tissue damage is progressive rather than immediate, because it is caused by the slow response of blood vessels and nerves to radiation rather than by a surgical cut.

The practical consequence is that a man six months after radiation has no useful information about where he will be at year three. Men who take early function as an all-clear are the ones most surprised later.

What radiation damages

Radiation targets the prostate, but the structures that produce an erection sit immediately adjacent to it: the cavernous nerves, the internal pudendal and cavernosal arteries, and the penile bulb.

The injury is primarily vascular and develops over time. Radiation damages the endothelium, the inner lining of blood vessels, and drives thickening, scarring, and eventual narrowing of small and medium-sized vessels. These changes appear months to years after exposure rather than immediately.

A rat model of image-guided stereotactic radiotherapy traced the sequence directly. Neuronal nitric oxide synthase expression in the cavernous nerve fell by four weeks after treatment, followed by reductions in smooth muscle content and blood perfusion in the corpora cavernosa, and the endpoint was corporal veno-occlusive dysfunction. The ratio of smooth muscle to collagen in the penile dorsal vessels dropped significantly at four and nine weeks.

That endpoint matters for how the problem presents. Corporal veno-occlusive dysfunction is the mechanism behind venous leak: erectile tissue that has lost smooth muscle and gained collagen cannot expand fully, and cannot compress the subtunical veins hard enough to hold blood in. Blood enters, but it does not stay.

This is why many men after radiation describe erections that begin adequately and then fade, rather than erections that never start.

What the long-term data show

The ProtecT trial is the most useful source, because it randomized men between active monitoring, surgery, and radiotherapy and then followed them for more than a decade with validated questionnaires.

At baseline, 67% of the men reported erections firm enough for intercourse. By six months this had fallen to 52% in the active monitoring group, 22% in the radiotherapy group, and 12% in the prostatectomy group. In the radiotherapy group the proportion then rose between six and twelve months before declining again.

That rise and fall is the curve worth understanding, and the explanation is in the next section.

The long-term picture is sobering for every group. At seven years, 27% of the radiotherapy group reported erections firm enough for intercourse, compared with 18% after prostatectomy and 30% under active monitoring. By twelve years all three groups had converged to between 13% and 17%.

Two things follow from this. Radiation does preserve function better than surgery in the medium term, so the standard counseling is not wrong. But the advantage narrows with time, and even men who were never treated at all lost substantial function over twelve years, because aging and vascular disease continue regardless of what happens to the prostate.

The hormone therapy confound

The ProtecT radiotherapy arm received neoadjuvant androgen deprivation alongside radiation, and this explains the shape of the early curve.

Androgen deprivation suppresses testosterone, which reduces desire and erectile capacity within weeks of starting. That accounts for the steep drop at six months. When the hormone course ends and testosterone recovers, function partially returns, which accounts for the rise between six and twelve months. The decline that follows is the radiation effect emerging on its own timescale.

If hormone therapy is part of a treatment plan, the early months reflect the hormones, and the later years reflect the radiation. Men who attribute everything to one or the other misread their own trajectory. Anyone on androgen deprivation should read the sexual side effects of that treatment separately, because it works through an entirely different mechanism.

Does the type of radiation matter

Yes, though less than the individual variables of baseline function, age, diabetes, and smoking status.

Reported rates of erectile dysfunction are generally lower after brachytherapy than after standard external beam radiation. Johns Hopkins puts the figures at roughly 25% to 50% after brachytherapy against close to 50% after standard external beam treatment.

Stereotactic body radiotherapy delivers higher doses per session, which raised early concern that potency outcomes would be worse. A study of 216 men treated with SBRT monotherapy found sexual outcomes comparable to conventional radiation approaches within the first twenty-four months, with longer follow-up needed to confirm the result.

Dose to the penile bulb and to the internal pudendal arteries is an active area of treatment planning research. It is a reasonable question to ask a radiation oncologist before treatment: whether the plan constrains dose to those structures, and what the trade-off against tumor coverage would be.

Can the decline be prevented

The honest answer is that no preventive protocol has been proven to work.

The most rigorous attempt was RTOG 0831, which randomized men undergoing radiotherapy to daily low-dose tadalafil or placebo. Among 221 evaluable men, 79% of the tadalafil group retained erectile function at 28 to 30 weeks, compared with 74% on placebo, a difference that was not statistically significant. At one year the figures were 72% and 71%. Partner-reported sexual satisfaction showed no significant effect either.

Daily PDE5 inhibitor use during radiation therefore has no demonstrated preventive value. This is a different question from whether PDE5 inhibitors help once erectile dysfunction has developed, where they clearly do help many men.

A systematic review of penile rehabilitation after both surgery and radiotherapy concluded that human results for PDE5 inhibitors are contradictory despite supportive animal data, that evidence for vacuum therapy, hyperbaric oxygen, and pelvic floor training is thin, and that clear rehabilitation guidelines do not yet exist.

What is well established is that modifiable vascular risk factors matter. Smoking, poorly controlled diabetes, and hypertension all damage the same small vessels that radiation damages. Addressing them does not undo radiation injury, but it removes an additional load from tissue that is already under strain.

What helps once function starts to decline

The sequence most urologists follow after radiation is broadly the same as for other causes of vasculogenic erectile dysfunction, with one difference. Response to oral medication after radiation tends to be better than after prostatectomy, because the cavernous nerves have not been cut. Many men who respond poorly to pills after surgery respond adequately after radiation, at least in the earlier years.

The usual progression is oral PDE5 inhibitors first, then vacuum erection devices, constriction devices, intracavernosal injections, and penile implants for men in whom nothing else is sufficient.

Where the decline follows the veno-occlusive pattern described above, retention is the limiting step rather than inflow. Erections build but do not hold, and firmness falls away before or during intercourse. Oral medication improves inflow and does comparatively little for retention, which is why some men find that pills produce a better start with no better outcome.

Xialla addresses that specific problem. Xialla is a soft silicone ring anchored so that it stays in position during intercourse, slowing venous outflow to keep blood in the erectile tissue. It works mechanically rather than pharmacologically, so it does not depend on nerve signaling or on a drug response, and it can be used alongside oral medication, injections, or a pump.

Xialla does not treat prostate cancer, reverse radiation injury, or restore the underlying tissue. It compensates for a retention problem, and it works only when a man can achieve some degree of erection to begin with, whether unaided or with another treatment.

What to track and what to ask

Erectile function after radiation changes slowly enough that it is easy to lose track of the trend. A validated questionnaire completed once or twice a year gives a more reliable picture than memory does, and gives a urologist something concrete to work from.

Questions worth raising with the treating team:

• Will hormone therapy form part of the plan, for how long, and what is expected as testosterone recovers?
• Does the radiation plan limit dose to the penile bulb and internal pudendal arteries?
• What is the realistic expectation at two years and at five, given baseline function, age, and vascular risk factors?
• Who manages sexual function after treatment ends, the radiation oncologist or a urologist, and when should the first review happen?
• If erections start but do not hold, what does that indicate, and what is offered for it?

A decline that begins two or three years after radiation is not a sign that treatment failed or that recovery was imagined. It is the expected course of a vascular injury that develops slowly, and it is treatable at every stage.

This article is for general education and is not medical advice. Consult a qualified healthcare provider about your individual situation.